Clinical trialNCT00890825CompletedPhase 2Interventional

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

SponsorAstraZenecaEnrollment88Non Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Dr. Gabriella Mariani
AstraZeneca, Hertfordshire, UK
Study Director
clinicaltrials.gov ↗
Dr. Pasi Janne
Dana-Farber Cancer Institute, Boston, USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

63 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Edegem, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Liège, Belgium

Brazil

Research Site
Belo Horizonte, Brazil
Research Site
Ijuí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria

Canada

Research Site
Oshawa, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada

Czechia

Research Site
Ostrava, Czechia
Research Site
Prague, Czechia
Research Site
Znojmo, Czechia

France

Research Site
Brest, France
Research Site
Clermont-Ferrand, France
Research Site
Dijon, France
Research Site
Lyon, France
Research Site
Marseille, France
Research Site
Rennes, France

Hungary

Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Győr, Hungary
Research Site
Mosdós, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Törökbálint, Hungary

23 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Selumetinib →PlaceboDocetaxel →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Apr 2009
Primary completion: 11 May 2011
Completion: 2 Nov 2016
Last update posted: 20 Jun 2018
Registered enrollment: 88
Registry id: NCT00890825

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.